Veradigm has been at the core of Allscripts’ business since May, following the divestiture of the vendor’s underperforming hospital and large practice EHR segments. Allscripts has been focusing on cleaning up its portfolio for a few years now, following a net loss in 2019 due in part to client attrition from acute care services. As part of this refresh, the vendor has been strategically investing in EHR-agnostic platforms, including in the areas of payment, data analytics, life sciences, and research marketplaces. That’s benefited Veradigm, which has continued to grow even as Allscripts’ other businesses struggled.
